CN: 32-1845/R
ISSN: 2095-6975
引用本文:
0
Rachel A. Ness, Duane D. Miller, Wei LI. The role of vitamin D in cancer prevention[J]. 中国天然药物英文, 2015, 13(7): 481-497

The role of vitamin D in cancer prevention

Rachel A. Ness, Duane D. Miller, Wei LI
Department of Pharmaceutical Sciences, University of Tennessee Health Sciences Center, Memphis, TN 38163, USA
摘要:
Vitamin D, also known as cholecalciferol, is the precursor to the active steroid hormone 1, 25-dihydroxyvitamin D3 (calcitriol; 1, 25(OH)2D3). The main physiological role for 1, 25(OH)2D3 is to regulate calcium and inorganic phosphate homeostasis for bone health. More recently, vitamin D has been investigated for its effects in the prevention and treatment of a variety of diseases such as cancer, autoimmune disorders, and cardiovascular disease. Preclinical data strongly support a role for vitamin D in the prevention of cancer through its anti-proliferative, pro-apoptotic, and anti-angiogenic effects on cells. Epidemiologic and clinical studies have shown mixed data on the correlation between serum vitamin D levels and cancer risk. This report seeks to outline results from the most recent preclinical and clinical studies investigating the potential role of vitamin D in cancer prevention.
关键词:    Vitamin D    Calcitriol    Cancer prevention    Cancer prognosis    Vitamin D deficiency   
收稿日期: 2015-05-10
Wei LI
相关功能
PDF(849 KB) Free
打印本文
把本文推荐给朋友
作者相关文章
Rachel A. Ness 在本刊中的所有文章
Duane D. Miller 在本刊中的所有文章
Wei LI 在本刊中的所有文章
参考文献:
[1] Garland CF, Garland FC. Do sunlight and vitamin D reduce the likelihood of colon cancer?[J]. Int J Epidemiol, 1980, 9(3):227-231.
[2] Krishnan AV, Trump DL, Johnson CS, et al. The role of vitamin D in cancer prevention and treatment[J]. Endocrin Metab Clin, 2010, 39(2):401-418.
[3] Feldman D, Krishnan AV, Swami S, et al. The role of vitamin D in reducing cancer risk and progression[J]. Nat Rev Cancer, 2014, 14(5):342-357.
[4] Feldman D, Pike JW, Adams JS. Vitamin D[M]. 3rd Ed Elsevier Academic Press, 2011.
[5] Moukayed M, Grant WB. Molecular link between vitamin D and cancer prevention[J]. Nutrients, 2013, 5(10):3993-4021.
[6] Deeb KK, Trump DL, Johnson CS. Vitamin D signalling pathways in cancer:potential for anticancer therapeutics[J]. Nat Rev Cancer, 2007, 7(9):684-700.
[7] Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D:an endocrine society scientific statement[J]. Endocr Rev, 2012, 33(3):456-492.
[8] Pereira F, Larriba MJ, Muñoz A. Vitamin D and colon cancer[J]. Endocr-Relat Cancer, 2012, 19(3):R51-R71.
[9] Wranicz J, Szostak-Wegierek D. Health outcomes of vitamin D. Part II. Role in prevention of diseases[J]. Rocz Panstw Zakl Hig, 2014, 65(4):273-279.
[10] Ross AC, Manson JE, Abrams SA, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the institute of medicine:What clinicians need to know[J]. J Clin Endocr Met, 2011, 96(1):53-58.
[11] Holick MF, Binkley NC, Bischoff-Ferrari HA, et al. Evaluation, treatment, and prevention of vitamin D deficiency:an endocrine society clinical practice guideline[J]. J Clin Endocr Met, 2011, 96(7):1911-1930.
[12] Hobaus J, Thiem UM, Hummel D, et al. Role of calcium, vitamin D, and the extrarenal vitamin D hydroxylases in carcinogenesis[J]. Anti-Cancer Agent Me, 2013, 13(1):20-35.
[13] Holick MF. Vitamin D and bone health[J]. J Nutr, 1996, 126(4 Suppl):1159S-1164S.
[14] Fleet JC, DeSmet M, Johnson R, et al. Vitamin D and cancer:a review of molecular mechanisms[J]. Biochem J, 2012, 441(1):61-76.
[15] Huhtakangas JA, Olivera CJ, Bishop JE, et al. The vitamin D receptor is present in caveolae-enriched plasma membranes and binds 1α,25(OH)2-Vitamin D3 in vivo and in vitro[J]. Mol Endocrinol, 2004, 18(11):2660-2671.
[16] Nemere I, Farach-Carson MC, Rohe B, et al. Ribozyme knockdown functionally links a 1, 25(OH)2D3 membrane binding protein (1, 25D3-MARRS) and phosphate uptake in intestinal cells[J]. P Natl A Sci USA, 2004, 101(19):7392-7397.
[17] Jensen SS, Madsen MW, Lukas J, et al. Inhibitory effects of 1alpha, 25-dihydroxyvitamin D(3) on the G(1)-S phasecontrolling machinery[J]. Mol Endocrinol, 2001, 15(8):1370-1380.
[18] Salehi-Tabar R, Nguyen-Yamamoto L, Tavera-Mendoza LE, et al. Vitamin D receptor as a master regulator of the c-MYC/MXD1 network[J]. P Natl A Sci USA, 2012, 109(46):18827-18832.
[19] Meyer MB, Goetsch PD, Pike JW. VDR/RXR and TCF4/betacatenin cistromes in colonic cells of colorectal tumor origin:impact on c-FOS and c-MYC gene expression[J]. Mol Endocrinol, 2012, 26(1):37-51.
[20] Washington MN, Kim JS, Weigel NL. 1alpha, 25-dihydroxyvitamin D3 inhibits C4-2 prostate cancer cell growth via a retinoblastoma protein (Rb)-independent G1 arrest[J]. Prostate, 2011, 71(1):98-110.
[21] Li P, Li C, Zhao X, et al. P27(Kip1) stabilization and G(1) arrest by 1, 25-dihydroxyvitamin D(3) in ovarian cancer cells mediated through down-regulation of cyclin E/cyclindependent kinase 2 and Skp1-Cullin-F-box protein/Skp2 ubiquitin ligase[J]. J Biol Chem, 2004, 279(24):25260-25267.
[22] Akutsu N, Lin R, Bastien Y, et al. Regulation of gene expression by 1alpha, 25-dihydroxyvitamin D3 and Its analog EB1089 under growth-inhibitory conditions in squamous carcinoma cells[J]. Mol Endocrinol, 2001, 15(7):1127-1139.
[23] Bao BY, Hu YC, Ting HJ, et al. Androgen signaling is required for the vitamin D-mediated growth inhibition in human prostate cancer cells[J]. Oncogene, 2004, 23(19):3350-3360.
[24] Chiang KC, Yeh CN, Chen SC, et al. MART-10, a new generation of vitamin D analog, Is more potent than 1alpha, 25-Dihydroxyvitamin D(3) in inhibiting cell proliferation and inducing apoptosis in ER+ MCF-7 breast cancer cells[J]. Evid-Based Compl Alt 2012, 2012:310872.
[25] Diaz GD, Paraskeva C, Thomas MG, et al. Apoptosis is induced by the active metabolite of vitamin D3 and its analogue EB1089 in colorectal adenoma and carcinoma cells:possible implications for prevention and therapy[J]. Cancer Res 2000, 60(8):2304-2312.
[26] Liu CY, Flesken-Nikitin A, Li S, et al. Inactivation of the mouse Brca1 gene leads to failure in the morphogenesis of the egg cylinder in early postimplantation development[J]. Genes Dev, 1996, 10(14):1835-1843.
[27] Pendas-Franco N, Aguilera O, Pereira F, et al. Vitamin D and Wnt/beta-catenin pathway in colon cancer:role and regulation of DICKKOPF genes[J]. Anticancer Res, 2008, 28(5A):2613-2623.
[28] Gocek E, Studzinski GP. Vitamin D and differentiation in cancer[J]. Crit Rev Cl Lab Sc, 2009, 46(4):190-209.
[29] Villaggio B, Soldano S, Cutolo M. 1, 25-dihydroxyvitamin D3 downregulates aromatase expression and inflammatory cytokines in human macrophages[J]. Clin Exp Rheumatol, 2012, 30(6):934-938.
[30] Kaler P, Augenlicht L, Klampfer L. Macrophage-derived IL-1beta stimulates Wnt signaling and growth of colon cancer cells:a crosstalk interrupted by vitamin D3[J]. Oncogene, 2009, 28(44):3892-3902.
[31] Kovalenko PL, Zhang Z, Cui M, et al. 1, 25 dihydroxyvitamin D-mediated orchestration of anticancer, transcript-level effects in the immortalized, non-transformed prostate epithelial cell line, RWPE1[J]. BMC Genomics, 2010, 11:26.
[32] Bao BY, Yao J, Lee YF. 1alpha, 25-dihydroxyvitamin D3 suppresses interleukin-8-mediated prostate cancer cell angiogenesis[J]. Carcinogenesis, 2006, 27(9):1883-1893.
[33] Tse AK, Zhu GY, Wan CK, et al. 1alpha, 25-Dihydroxyvitamin D3 inhibits transcriptional potential of nuclear factor kappa B in breast cancer cells[J]. Mol immunol, 2010, 47(9):1728-1738.
[34] Dormoy V, Beraud C, Lindner V, et al. Vitamin D3 triggers antitumor activity through targeting hedgehog signaling in human renal cell carcinoma[J]. Carcinogenesis, 2012, 33(11):2084-2093.
[35] Krishnan AV, Shinghal R, Raghavachari N, et al. Analysis of vitamin D-regulated gene expression in LNCaP human prostate cancer cells using cDNA microarrays[J]. Prostate, 2004, 59(3):243-251.
[36] Figueroa JA, De Raad S, Tadlock L, et al. Differential expression of insulin-like growth factor binding proteins in high versus low Gleason score prostate cancer[J]. J Urology, 1998, 159(4):1379-1383.
[37] Kriebitzsch C, Verlinden L, Eelen G, et al. The impact of 1, 25(OH)2D3 and its structural analogs on gene expression in cancer cells--a microarray approach[J]. Anticancer Res, 2009, 29(9):3471-3483.
[38] Lee HJ, Liu H, Goodman C, et al. Gene expression profiling changes induced by a novel gemini vitamin D derivative during the progression of breast cancer[J]. Biochem Pharmacol, 2006, 72(3):332-343.
[39] Swami S, Raghavachari N, Muller UR, et al. Vitamin D growth inhibition of breast cancer cells:gene expression patterns assessed by cDNA microarray[J]. Breast Cancer Res Tr, 2003, 80(1):49-62.
[40] Palmer HG, Gonzalez-Sancho JM, Espada J, et al. Vitamin D(3) promotes the differentiation of colon carcinoma cells by the induction of E-cadherin and the inhibition of beta-catenin signaling[J]. J Cell Biol, 2001, 154(2):369-387.
[41] Beildeck ME, Islam M, Shah S, et al. Control of TCF-4 expression by VDR and vitamin D in the mouse mammary gland and colorectal cancer cell lines[J]. PLoS ONE, 2009, 4(11):e7872.
[42] Rohan JN, Weigel NL. 1Alpha, 25-dihydroxyvitamin D3 reduces c-Myc expression, inhibiting proliferation and causing G1 accumulation in C4-2 prostate cancer cells[J]. Endocrinology, 2009, 150(5):2046-2054.
[43] Rawson JB, Sun Z, Dicks E, et al. Vitamin D intake is negatively associated with promoter methylation of the Wnt antagonist gene DKK1 in a large group of colorectal cancer patients[J]. Nutr Cancer, 2012, 64(7):919-928.
[44] Aguilera O, Pena C, Garcia JM, et al. The Wnt antagonist DICKKOPF-1 gene is induced by 1alpha, 25-dihydroxyvitamin D3 associated to the differentiation of human colon cancer cells[J]. Carcinogenesis, 2007, 28(9):1877-1884.
[45] Ben-Shoshan M, Amir S, Dang DT, et al. 1alpha, 25-dihydroxyvitamin D3(Calcitriol) inhibits hypoxia-inducible factor-1/vascular endothelial growth factor pathway in human cancer cells[J]. Mol Cancer Ther, 2007, 6(4):1433-1439.
[46] Chung I, Han G, Seshadri M, et al. Role of vitamin D receptor in the antiproliferative effects of calcitriol in tumor-derived endothelial cells and tumor angiogenesis in vivo[J]. Cancer Res 2009, 69(3):967-975.
[47] Morelli S, Buitrago C, Boland R, et al. The stimulation of MAP kinase by 1, 25(OH)(2)-vitamin D(3) in skeletal muscle cells is mediated by protein kinase C and calcium[J]. Mol Cell Endocrinol, 2001, 173(1-2):41-52.
[48] Goeman F, De Nicola F, De Meo PD, et al. VDR primary targets by genome-wide transcriptional profiling[J]. J Steroid Biochem, 2014, 143:348-356.
[49] Beaudin SG, Robilotto S, Welsh J. Comparative regulation of gene expression by 1, 25-dihydroxyvitamin D3 in cells derived from normal mammary tissue and breast cancer[J]. J Steroid Biochem, 2015, 148:96-102.
[50] Zhang Z, Zhang H, Hu Z, et al. Synergy of 1, 25-dihydroxyvitamin D3 and carboplatin in growth suppression of SKOV-3 cells[J]. Oncol Lett, 2014, 8(3):1348-1354.
[51] Linnewiel-Hermoni K, Khanin M, Danilenko M, et al. The anti-cancer effects of carotenoids and other phytonutrients resides in their combined activity[J]. Arch Biochem Biophys, 2015, 572:28-35.
[52] Meeker S, Seamons A, Paik J, et al. Increased dietary vitamin D suppresses MAPK signaling, colitis, and colon cancer[J]. Cancer Res, 2014, 74(16):4398-4408.
[53] Rebel H, der Spek CD, Salvatori D, et al. UV exposure inhibits intestinal tumor growth and progression to malignancy in intestine-specific Apc mutant mice kept on low vitamin D diet[J]. Int J Cancer, 2015, 136(2):271-277.
[54] Kasiappan R, Sun Y, Lungchukiet P, et al. Vitamin D suppresses leptin stimulation of cancer growth through microRNA[J]. Cancer Res, 2014, 74(21):6194-6204.
[55] Lang K, Ratke J. Leptin and adiponectin:new players in the field of tumor cell and leukocyte migration[J]. Cell Commun Signal, 2009, 7:27.
[56] Skaaby T, Husemoen LL, Thyssen JP, et al. Filaggrin loss-offunction mutations and incident cancer:a population-based study[J]. Brit J Dermatol, 2014, 171(6):1407-1414.
[57] Irvine AD, McLean WH, Leung DY. Filaggrin mutations associated with skin and allergic diseases[J]. New Engl J Med, 2011, 365(14):1315-1327.
[58] Thyssen JP, Thuesen B, Huth C, et al. Skin barrier abnormality caused by filaggrin (FLG) mutations is associated with increased serum 25-hydroxyvitamin D concentrations[J]. J Allergy Clin Immun, 2012, 130(5):1204-1207.e1202.
[59] Moy KA, Mondul AM, Zhang H, et al. Genome-wide association study of circulating vitamin D-binding protein[J]. Am J Clin Nutr, 2014, 99(6):1424-1431.
[60] Ashktorab H, Nguza B, Fatemi M, et al. Case-control study of vitamin D, dickkopf homolog 1(DKK1) gene methylation, VDR gene polymorphism and the risk of colon adenoma in African Americans[J]. PLoS ONE, 2011, 6(10):e25314.
[61] Atoum MF, Tchoporyan MN. Association between circulating vitamin D, the Taq1 vitamin D receptor gene polymorphism and colorectal cancer risk among Jordanians[J]. Asian Pac J Cancer Prev, 2014, 15(17):7337-7341.
[62] Kostner K, Denzer N, Muller CSL, et al. The relevance of Vitamin D receptor (VDR) gene polymorphisms for cancer:a review of the literature[J]. Anticancer Res, 2009, 29(9):3511-3536.
[63] Serrano D, Gnagnarella P, Raimondi S, et al. Meta-analysis on vitamin D receptor and cancer risk:focus on the role of TaqI, ApaI, and Cdx2 polymorphisms[J]. Eur J Cancer Prev, 2015.
[64] Gnagnarella P, Pasquali E, Serrano D, et al. Vitamin D receptor polymorphism FokI and cancer risk:a comprehensive meta-analysis[J]. Carcinogenesis, 2014, 35(9):1913-1919.
[65] Raimondi S, Pasquali E, Gnagnarella P, et al. BsmI polymorphism of vitamin D receptor gene and cancer risk:A comprehensive meta-analysis[J]. Mut Res-Fund Mol M, 2014, 769:17-34.
[66] Anderson LN, Cotterchio M, Knight JA, et al. Genetic variants in Vitamin D pathway genes and risk of pancreas cancer; results from a population-based case-control study in Ontario, Canada[J]. PLoS ONE, 2013, 8(6):e66768.
[67] Kim Y, Je Y. Vitamin D intake, blood 25(OH)D levels, and breast cancer risk or mortality:a meta-analysis[J]. Br J Cancer, 2014, 110(11):2772-2784.
[68] Wang J, Eliassen AH, Spiegelman D, et al. Plasma free 25-hydroxyvitamin D, vitamin D binding protein, and risk of breast cancer in the Nurses' Health Study II[J]. Cancer Cause Contr, 2014, 25(7):819-827.
[69] Li M, Chen P, Li J, et al. Review:the impacts of circulating 25-hydroxyvitamin D levels on cancer patient outcomes:a systematic review and meta-analysis[J]. J Clin Endocr Met, 2014, 99(7):2327-2336.
[70] Weinstein SJ, Purdue MP, Smith-Warner SA, et al. Serum 25-hydroxyvitamin D, vitamin D binding protein and risk of colorectal cancer in the prostate, lung, colorectal and ovarian cancer screening trial[J]. Int J Cancer, 2015, 136(6):E654-E664.
[71] Anic GM, Weinstein SJ, Mondul AM, et al. Serum vitamin D, vitamin D binding protein, and risk of colorectal cancer[J]. PLoS One, 2014, 9(7):e102966.
[72] Zgaga L, Theodoratou E, Farrington SM, et al. Plasma vitamin D concentration influences survival outcome after a diagnosis of colorectal cancer[J]. J Clin Oncol, 2014, 32(23):2430-2439.
[73] Kristal AR, Till C, Song X, et al. Plasma vitamin D and prostate cancer risk:results from the selenium and Vitamin E cancer prevention trial[J]. Cancer Epidem Biomar, 2014, 23(8):1494-1504.
[74] Schenk JM, Till CA, Tangen CM, et al. Serum 25-hydroxyvitamin D concentrations and risk of prostate cancer:results from the prostate cancer prevention trial[J]. Cancer Epidem Biomar, 2014, 23(8):1484-1493.
[75] Cheng TY, Goodman GE, Thornquist MD, et al. Estimated intake of vitamin D and its interaction with vitamin A on lung cancer risk among smokers[J]. Int J Cancer, 2014, 135(9):2135-2145.
[76] Ng K, Scott JB, Drake BF, et al. Dose response to vitamin D supplementation in African Americans:results of a 4-arm, randomized, placebo-controlled trial[J]. Am J Clin Nutr, 2014, 99(3):587-598.
[77] Chandler PD, Scott JB, Drake BF, et al. Impact of vitamin D supplementation on inflammatory markers in African Americans:results of a four-arm, randomized, placebocontrolled trial[J]. Cancer Prev Res 2014, 7(2):218-225.
[78] Fabian C. Modulation of breast cacner risk biomarkers by high dose vitamin D[J]. ClinicalTrials.gov, 2010.
[79] University of Illinois at Chicago. Efficacy of vitamin D in colorectal cancer chemoprevention[EB/OL]. 2012:ClinicalTrials.gov.
[80] Murphy AB, Nyame Y, Martin IK, et al. Vitamin D deficiency predicts prostate biopsy outcomes[J]. Clin Cancer Res, 2014, 20(9):2289-2299.
[81] Shui IM, Mucci LA, Kraft P, et al. Vitamin D-related genetic variation, plasma vitamin D, and risk of lethal prostate cancer:a prospective nested case-control study[J]. J Natl Cancer I, 2012, 104(9):690-699.
[82] Gambichler T, Bindsteiner M, Hoxtermann S, et al. Serum 25-hydroxyvitamin D serum levels in a large German cohort of patients with melanoma[J]. Brit J Dermatol, 2013, 168(3):625-628.
[83] Bade B, Zdebik A, Wagenpfeil S, et al. Low serum 25-hydroxyvitamin d concentrations are associated with increased risk for melanoma and unfavourable prognosis[J]. PLoS ONE, 2014, 9(12):e112863.
[84] Wesa KM, Segal NH, Cronin AM, et al. Serum 25-hydroxy vitamin D and survival in advanced colorectal cancer:a retrospective analysis[J]. Nutr Cancer, 2015, 67(3):424-430.
[85] Lee HJ, Muindi JR, Tan W, et al. Low 25(OH) vitamin D3 levels are associated with adverse outcome in newly diagnosed, intensively treated adult acute myeloid leukemia[J]. Cancer, 2014, 120(4):521-529.
[86] Peiris AN, Bailey BA, Manning T. Relationship of vitamin D monitoring and status to bladder cancer survival in veterans[J].South Med J, 2013, 106(2):126-130.
[87] Houghton LA, Vieth R. The case against ergocalciferol (vitamin D2) as a vitamin supplement[J]. Am J Clin Nutr, 2006, 84(4):694-697.
[88] Leyssens C, Verlinden L, Verstuyf A. The future of vitamin D analogs[J]. Front Physiol, 2014, 5:122.
[89] Mazzaferro S, Goldsmith D, Larsson TE, et al. Vitamin D metabolites and/or analogs:which D for which patient?[J]. Curr Vasc Pharmacol, 2014, 12(2):339-349.
[90] Cheung FS, Lovicu FJ, Reichardt JK. Current progress in using vitamin D and its analogs for cancer prevention and treatment[J]. Expert Rev Anticanc, 2012, 12(6):811-837.
[91] Brown AJ, Slatopolsky E. Vitamin D analogs:therapeutic applications and mechanisms for selectivity[J]. Mol Aspects Med, 2008, 29(6):433-452.
[92] Sintov AC, Yarmolinsky L, Dahan A, et al. Pharmacological effects of vitamin D and its analogs:recent developments[J]. Drug Discov Today, 2014, 19(11):1769-1774.
[93] Hylander E, Jarnum S. 1α-Hydroxyvitamin D3 in Intestinal Calcium Malabsorption[J]. Scand J Gastroentero, 1980, 15(4):443-448.
[94] Hellstrom E, Robert KH, Samuelsson J, et al. Treatment of myelodysplastic syndromes with retinoic acid and 1 alphahydroxy-vitamin D3 in combination with low-dose ara-C is not superior to ara-C alone. Results from a randomized study. The Scandinavian Myelodysplasia Group (SMG)[J]. Eur J Haematol, 1990, 45(5):255-261.
[95] Motomura S, Kanamori H, Maruta A, et al. The effect of 1-hydroxyvitamin D3 for prolongation of leukemic transformation-free survival in myelodysplastic syndromes[J]. Am J Hematol, 1991, 38(1):67-68.
[96] Petrini M, Caracciolo F, Corini M, et al. Low-dose ARA-C and 1(OH) D3 administration in acute non lymphoid leukemia:pilot study[J]. Haematologica, 1991, 76(3):200-203.
[97] Petrini M, Caracciolo F, Carulli G, et al. Vitamin D3 administration and multidrug resistance in acute nonlymphoblastic leukemia[J]. Acta Haematol-Basel, 1993, 89(4):184-188.
[98] Trouillas P, Honnorat J, Bret P, et al. Redifferentiation therapy in brain tumors:long-lasting complete regression of glioblastomas and an anaplastic astrocytoma under long term 1-alpha-hydroxycholecalciferol[J]. J Neuro-Oncol, 2001, 51(1):57-66.
[99] Obara W, Mizutani Y, Oyama C, et al. Prospective study of combined treatment with interferon-alpha and active vitamin D3 for Japanese patients with metastatic renal cell carcinoma[J]. Int J Urol, 2008, 15(9):794-799.
[100] Binderup L, Bramm E. Effects of a novel vitamin D analogue MC903 on cell proliferation and differentiation in vitro and on calcium metabolism in vivo[J]. Biochem Pharmacol, 1988, 37(5):889-895.
[101] Bower M, Colston KW, Stein RC, et al. Topical calcipotriol treatment in advanced breast cancer[J]. Lancet, 1991, 337(8743):701-702.
[102] O'Brien ME, Talbot D, Maclennan K, et al. Inefficacy of calcipotriol in skin metastases from breast cancer[J]. Lancet, 1993, 342(8877):994.
[103] Liu G, Oettel K, Ripple G, et al. Phase I trial of 1α-hydroxyvitamin D2 in patients with hormone refractory prostate cancer[J]. Clin Cancer Res, 2002, 8(9):2820-2827.
[104] Liu G, Wilding G, Staab MJ, et al. Phase II study of 1α-hydroxyvitamin D2 in the treatment of advanced androgen-independent prostate cancer[J]. Clin Cancer Res, 2003, 9(11):4077-4083.
[105] Attia S, Eickhoff J, Wilding G, et al. Randomized, doubleblinded phase II evaluation of docetaxel with or without doxercalciferol in patients with metastatic, androgen-independent prostate cancer[J]. Clin Cancer Res, 2008, 14(8):2437-2443.
[106] Gee J, Bailey H, Kim K, et al. Phase II open label, multi-center clinical trial of modulation of intermediate endpoint biomarkers by 1α-hydroxyvitamin D2 in patients with clinically localized prostate cancer and high grade pin[J]. Prostate, 2013, 73(9):970-978.
[107] Petrich A, Kahl B, Bailey H, et al. Phase II study of doxercalciferol for the treatment of myelodysplastic syndrome[J]. Leukemia Lymphoma, 2008, 49(1):57-61.
[108] M. D. Anderson Cancer Center. Doxercalciferol in recurrent pediatric solid tumors[EB/OL]. 2007:ClinicalTrials.gov.
[109] Zhou JY, Norman AW, Lubbert M, et al. Novel vitamin D analogs that modulate leukemic cell growth and differentiation with little effect on either intestinal calcium absorption or bone mobilization[J]. Blood, 1989, 74(1):82-93.
[110] Wieder R, Novick SC, Hollis BW, et al. Pharmacokinetics and safety of ILX23-7553, a non-calcemic-vitamin D3 analogue, in a phase I study of patients with advanced malignancies[J]. Invest New Drug, 2003, 21(4):445-452.
[111] Jain RK, Trump DL, Egorin MJ, et al. A phase I study of the vitamin D3 analogue ILX23-7553 administered orally to patients with advanced solid tumors[J]. Invest New Drug, 2011, 29(6):1420-1425.
[112] Verlinden L, Verstuyf A, Van Camp M, et al. Two novel 14-Epi-analogues of 1, 25-dihydroxyvitamin D3 inhibit the growth of human breast cancer cells in vitro and in vivo[J]. Cancer Res, 2000, 60(10):2673-2679.
[113] Medioni J, Deplanque G, Ferrero JM, et al. Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patients[J]. Clin Cancer Res, 2014, 20(17):4471-4477.
[114] Hybrigenics launches phase II clinical study of inecalcitol in chronic myeloid leukemia[C]. LSP, 2015.
[115] Chen TC, Schwartz GG, Burnstein KL, et al. The in vitro evaluation of 25-hydroxyvitamin D3 and 19-nor-1alpha, 25-dihydroxyvitamin D2 as therapeutic agents for prostate cancer[J]. Clin Cancer Res, 2000, 6(3):901-908.
[116] Schwartz GG, Hall MC, Stindt D, et al. Phase I/II study of 19-nor-1alpha-25-dihydroxyvitamin D2(paricalcitol) in advanced, androgen-insensitive prostate cancer[J]. Clin Cancer Res, 2005, 11(24 Pt 1):8680-8685.
[117] Lawrence JA, Akman SA, Melin SA, et al. Oral paricalcitol (19-nor-1, 25-dihydroxyvitamin D2) in women receiving chemotherapy for metastatic breast cancer:a feasibility trial[J]. Cancer Biol Ther, 2013, 14(6):476-480.
[118] Colston KW, Mackay AG, James SY, et al. EB1089:a new vitamin D analogue that inhibits the growth of breast cancer cells in vivo and in vitro[J]. Biochem Pharmacol, 1992, 44(12):2273-2280.
[119] Gulliford T, English J, Colston KW, et al. A phase I study of the vitamin D analogue EB 1089 in patients with advanced breast and colorectal cancer[J]. Brit J Cancer, 1998, 78(1):6-13.
[120] Evans TR, Colston KW, Lofts FJ, et al. A phase II trial of the vitamin D analogue Seocalcitol (EB1089) in patients with inoperable pancreatic cancer[J]. Brit J Cancer, 2002, 86(5):680-685.
[121] Dalhoff K, Dancey J, Astrup L, et al. A phase II study of the vitamin D analogue Seocalcitol in patients with inoperable hepatocellular carcinoma[J]. Brit J Cancer, 2003, 89(2):252-257.
[122] LEO Pharma. Seocalcitol versus placebo in advanced hepatocellular carcinoma[J]. Clinical Trials. Gov, 2007.
[123] LEO Pharma. Seocalcitol versus placebo in the adjuvant treatment of hepatocellular carcinoma[J]. Clinical Trials. Gov, 2007.
[124] Brard L, Lange TS, Robison K, et al. Evaluation of the first Ergocalciferol-derived, non hypercalcemic anti-cancer agent MT19c in ovarian cancer SKOV-3 cell lines[J]. Gynecol Oncol, 2011, 123(2):370-378.
[125] Chen B, Kawai M, Wu-Wong JR. Synthesis of VS-105:A novel and potent vitamin D receptor agonist with reduced hypercalcemic effects[J]. Bioorg Med Chem Lett, 2013, 23(21):5949-5952.
[126] Ma Y, Yu WD, Hidalgo AA, et al. Inecalcitol, an analog of 1, 25D3, displays enhanced antitumor activity through the induction of apoptosis in a squamous cell carcinoma model system[J]. Cell Cycle, 2013, 12(5):743-752.
[127] Chen J, Wang J, Kim TK, et al. Novel vitamin D analogs as potential therapeutics:metabolism, toxicity profiling, and antiproliferative activity[J]. Anticancer Res, 2014, 34(5):2153-2163.
[128] Chiang KC, Yeh CN, Hsu JT, et al. The vitamin D analog, MART-10, represses metastasis potential via downregulation of epithelial-mesenchymal transition in pancreatic cancer cells[J]. Cancer Lett, 2014, 354(2):235-244.
[129] Deluca HF. The development of a bone- and parathyroidspecific analog of vitamin D:2-methylene-19-nor-(20S)-1alpha, 25-dihydroxyvitamin D3[J]. Bonekey Rep, 2014, 3:514.
[130] Kudo T, Ishizawa M, Maekawa K, et al. Combination of triple bond and adamantane ring on the vitamin D side chain produced partial agonists for vitamin D receptor[J]. J Med Chem, 2014, 57(10):4073-4087.
[131] Slominski AT, Zmijewski MA, Semak I, et al. Cytochromes p450 and skin cancer:role of local endocrine pathways[J]. Anticancer Agents Med Chem, 2014, 14(1):77-96.
[132] Fred Hutchison Cancer Research Center. Vitamin D, diet, and activity study (ViDA)[EB/OL]. 2010:ClinicalTrials.gov, NCT01240213.
[133] Shanghai Jiao Tong University School of Medicine. Study of folic acid, calcium and Vitamin D in preventing colorectal polyps and colorectal cancer[EB/OL]. 2014:ClinicalTrials.gov, NCT0206688.
[134] Brigham and Women's Hospital. Vitamin and Omega-3 Trial (VITAL)[EB/OL]. 2010:ClinicalTrials.gov, NCT01169259.
[135] University of Eastern Finland. Finnish Vitamin D Trial (FIND)[EB/OL]. 2011:ClinicalTrials.gov, NCT01463813.
[136] Emory University. Calcium/Vitamin D, biomarkers & colon polyp prevention (PPS4B)[EB/OL]. 2006:ClinicalTrials.gov, NCT00399607.
[137] Southwest Oncology Group. S0812 high dose cholecalciferol in premenopausal women at high-risk for breast cancer[EB/OL]. 2010:ClinicalTrials.gov, NCT01097278.
[138] Johns Hopkins University. Study of high-dose oral Vitamin D for the prevention of liver cancer[EB/OL]. 2013:ClinicalTrials.gov, NCT01956864.
[139] Creighton University. Clinical trial of Vitamin D3 to reduce cancer risk in postmenopausal women (CAPS)[EB/OL]. 2010:ClinicalTrials.gov, NCT01052051.